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Abstract
We report the successful angioplasty of an acute arterial narrowing
after suture-mediated closure (SMC) of a femoral arterial puncture.
A 75-year-old woman underwent a cerebral arteriogram via a right
common femoral artery puncture. The arteriotomy site was closed
with a SMC device. Four days after placement the patient com-
plained of pain in her right calf after walking. An arteriogram 7
days after SMC showed a severe focal stenosis at the origin of the
superficial femoral artery involving the presumed puncture site. The
lesion was successfully treated with balloon angioplasty. The pa-
tient at 6 months was asymptomatic.
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The use of access site closure devices has expanded rapidly in the
past several years. Initial reports indicated remarkable safety with
these devices; however, a review of the literature reveals a small
number of major complications [1, 2]. Angio-Seal has the highest
rate of major complications (3.2%), followed in descending order
by Perclose (2.3%), manual compression (1.0%), and Vasoseal
(0.6%) [3, 4]. It is important for the interventionalist utilizing these
devices to be aware of potential problems, recognize when they
occur, and then be able to determine a proper course of treatment.
This case report describes balloon angioplasty in the manage-
ment of a puncture-site arterial stenosis complicating suture-medi-
ated closure (SMC) of the arterial puncture.
Case Report
A 75-year-old woman underwent a cerebral angiogram from a right com-
mon femoral artery puncture for evaluation of transient ischemic attacks.
The right common femoral artery was accessed with a #19 gauge single-
wall needle and a 5 Fr sheath placed. After the procedure, a femoral
arteriogram was performed and the arteriotomy site was closed with a SMC
device (Closer, Perclose, Menlo Park, CA, USA) (Fig. 1A) without imme-
diate complication. The evening after the cerebral arteriogram the patient
complained of pain in her right groin radiating down her leg. The patient
was afebrile and her white blood cell count was normal. Her distal pulses
were palpable with no preprocedural change. There was no evidence of a
hematoma or bruit at the puncture site. The patient was discharged the day
after the arteriogram, and the groin pain resolved 3 days after the procedure.
One week later the patient presented with acute right calf claudication
(approximately 100 yards) and was re-admitted to the hospital. The right
ankle brachial index (ABI) was 0.36 (preprocedural ABI  0.93). A right
lower extremity arteriogram was performed from the left femoral approach,
which showed a tight stenosis at the origin of the right superficial femoral
artery (Fig. 1B). After discussion with the referring vascular surgeon, a
decision was made to treat the lesion with balloon angioplasty. A 5.5 Fr
contralateral introducer (Balkin, Cook, Bloomington, IN, USA) was ad-
vanced into the right external iliac artery. The proximal superficial femoral
artery stenosis was negotiated with a 4 Fr hydrophilic-coated Cobra catheter
and a 0.035 inch angled hydrophilic-coated torque wire (Medi-tech, Water-
town, MA, USA) using road-mapping. Angioplasty was performed with a 4
mm diameter  20 mm long RxVIA/TRAC 14 monorail balloon catheter
over a 0.014 inch Sparta Core wire (Guidant, Temecula, CA, USA) to 10
atm (147 psi, balloon diameter 4.08 mm at 10 atm). The lesion was further
dilated with a 5 mm diameter  20 mm long RxVIA/TRAC 14 monorail
balloon catheter. The waist was eliminated after inflating the balloon to 15
atm (220.5 psi, balloon diameter  5.37 mm at 15 atm). The final arterio-
gram revealed no residual stenosis and excellent blood flow in the superfi-
cial femoral artery was noted (Fig. 1C).
The following day after the balloon angioplasty, ankle pressure mea-
surement revealed an ABI of 0.88. The patient had no claudication symp-
toms. The patient has remained asymptomatic for 6 months after
angioplasty.
Discussion
Arterial narrowing related to the use of a SMC device is rare. To
our knowledge there has been no published report on the use of
balloon angioplasty in the management of puncture site stenosis
complicating the use of a closure device.
The three commonly used SMC devices are the Closer, Prostar
XL, and Prostar plus (Perclose, Menlo Park, CA, USA). The Closer
is the current 6 Fr platform, which replaced the Techstar 6 Fr
system and is indicated for use in 5 and 6 Fr sheath access sites. The
device is inserted over a standard guidewire until pulsatile flow is
present through a marker lumen. Footplates are deployed inside the
vessel and the device is retracted until flow ceases in the marker
lumen. Two needles are then deployed from outside the vessel into
the footplates and the suture (3-0 polyester) is captured and pulled
through the arterial wall and subsequently through the device. The
sutures are then retrieved and a clinch knot is tied using a knot-
tying device. The delivery system is removed and the knot is pulled
down to the arteriotomy with tension on the rail suture. A knot
pusher is then used to push the knot securely against the arterial
wall.
The polyester surgical sutures with the Closer system elicit a
minimal acute inflammatory reaction in tissues, followed by grad-
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ual encapsulation of the suture by fibrous connective tissue [5].
Polyester surgical sutures are not absorbed, nor is any significant
change in tensile strength known to occur in vivo.
It is our belief that the inflammatory reaction may have contrib-
uted to the stenosis in our patient. The patient did complain of pain
at the puncture site, which may have been related to the inflamma-
tory reaction; however, there was no erythema or warmth at the
puncture site. Some authors have advocated excluding balloon
angioplasty in patients with inflammatory arteritis with serologic
evidence of active disease (elevated erythrocyte sedimentation rate
or C-reactive protein), although the effect of disease activity on the
outcome of angioplasty is unknown [6]. However, Dong et al. [7]
reported an 86% clinical success 6 months after renal angioplasty in
patients with Takayasu’s arteritis, even though 45% of the patients
had an elevated erythrocyte sedimentation rate at the time of
dilatation. In our case the patient did respond to balloon angioplasty
even though there may have been underlying inflammation at the
SMC site.
Thrombus formation at the SMC site may be another potential
cause for the stenosis. This could occur from the trauma caused to
the endothelium from the puncture or deployment of the SMC
device. Furthermore, the suture material acting as a foreign body
could also promote thrombus formation.
We were initially reluctant to perform balloon dilatation on the
arteriotomy site 1 week after the initial puncture, because of the
theoretical risk of rupturing the artery or creating a pseudoaneu-
rysm. However, after further discussion with the vascular surgeon
we proceeded with balloon angioplasty. The region was dilated
only to 5 mm to avoid potential complications because of the recent
arteriotomy. At 6 months there was no evidence of a pseudoaneu-
rysm by clinical examination.
SMC devices were studied in the STAND I and STAND II
Trials [8]. STAND I evaluated the 6 Fr Techstar device in 200
patients following catheterization with 5 Fr, 6 Fr, or 6.5 Fr sheaths.
Major complications occurred in 2 patients (1%), 1 patient under-
went surgical repair for a pseudoaneurysm, and 1 patient developed
local site infection requiring outpatient antibiotics. Minor compli-
cations occurred in 3 patients (1.5%); 1 patient developed a hema-
toma 6 cm, and 2 patients developed a small pseudoaneurysm
requiring no further therapy. Postprocedural ultrasound studies
were obtained in the first 73 patients per protocol: 2 patients had a
small pseudoaneurysm as described above, and no patient had
intra-arterial thrombus or luminal narrowing at the closure site.
The STAND II Trial was a multicenter study of 515 patients
randomized to SMC versus traditional compression. A sheath size
8 Fr was used in 57% of patients. Major complications occurred
in 2.4% of the suture closure group and 1.1% of the compression
group (p  NS). The median time to hemostasis (19 vs 243 min, p
 0.01) and time to ambulation (3.9 vs 14.8 h, p  0.01) were
significantly shorter for SMC.
The Closer European (CE) Trial was a multicenter registry of
200 patients which examined the safety and effectiveness of the
Closer 6 Fr SMC system. The study was designed to detect differ-
ences in the observed incidence of major complications at 30 days
relative to two pre-specified historical control groups of patients
undergoing diagnostic procedures. Major complications occurred in
no patients. Minor complications occurred in 5 patients (2.5%; 3
patients (1.5%) developed a hematoma  6 cm, 1 patient (0.5%)
developed vessel narrowing at the insertion site which was success-
ful treated by balloon angioplasty, and 1 patient (0.5%) developed
an arteriovenous fistula. The results have not been published in a
journal, but are available on the Perclose website [9].
In October 1999, the FDA Center for Devices and Radiological
Health issued a warning statement and recommendations related to
the use of vascular hemostasis devices [10]. Table 1 summarizes the
FDA recommendations.
Fig. 1. A Right femoral anteroposterior digital subtraction arteriogram (DSA) taken before closure of the puncture site shows a 5 Fr sheath
in the common femoral artery immediately proximal to the origins of the deep and superficial femoral arteries. The small arrow indicates the
presumed site of the arterial puncture. Note the true femoral bifurcation is not seen in profile. The bifurcation is higher, as shown by the larger
arrow. B One week after the procedure a right femoral DSA was performed from a left femoral approach, showing a severe stenosis (arrow)
at the origin of the diminutive superficial femoral artery and a moderate narrowing at the origin of the deep femoral artery. C Post-angioplasty
arteriogram shows satisfactory dilatation of the stenosis with excellent flow in the superficial femoral artery. The stenosis of the deep femoral
artery is again seen.
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The FDA’s recommendations were followed during deployment
of the device in our patient. A single-wall anterior puncture was
utilized. The postprocedural management instructions and ambula-
tion recommendations were followed. The patient was not on
glycoprotein IIB/IIIA inhibitors or anticoagulated.
It is our belief the anteroposterior (AP) femoral arteriogram
before the arterial access closure shows a low puncture of the
common femoral artery just above the origins of the superficial and
deep femoral arteries (Fig. 1A). The femoral bifurcation is not in
profile. An ipsilateral oblique projection would show the true punc-
ture site to be lower than on the AP arteriogram involving the origin
of the superficial femoral artery. This additionally likely contrib-
uted to the stenosis, since the manufacture recommends puncturing
the middle portion of the common femoral artery. Since this com-
plication we have performed an ipsilateral oblique and AP arterio-
gram on all patients before placing a SMC device. If the puncture
site is near the femoral bifurcation we do not use a SMC device.
In summary, stenoses caused by placement of the 6 Fr SMC
device can be successfully treated with balloon angioplasty, elim-
inating the need for surgery. Making sure the arteriotomy site is
over the middle of the common femoral artery may limit this
complication.
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Table 1. FDA recommendations to minimize injuries involving closure
devices
1. Carefully follow the manufacturer’s warnings, precautions, and
instructions
2. Do not use these devices to treat patients with suspected punctures of
the posterior wall
3. Monitor the groin site to minimize the occurrence of complications
4. Weigh the risks of bleeding at the puncture site against the benefits of
using the closure device when treating patients with bleeding disorders
or patients medicated with glycoprotein IIb/IIIa inhibitors
5. Observe postprocedural patient management instructions and
ambulation recommendations for the closure device
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